Uniqure NVNASDAQ:QURE
- LAST PRICE4.3950
- TODAY'S CHANGE (%)-0.0650 (-1.4574%)
- Bid / Lots4.3900/ 8
- Ask / Lots4.4000/ 13
- Open / Previous Close4.4900 / 4.4600
- Day Range
- 52 Week Range
- Volume320,484
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | QURE |
|---|---|---|
| 09:32 ET | 3699 | 4.45 |
| 09:34 ET | 300 | 4.42 |
| 09:36 ET | 100 | 4.42 |
| 09:38 ET | 400 | 4.42 |
| 09:43 ET | 100 | 4.45 |
| 09:45 ET | 9083 | 4.44 |
| 09:52 ET | 100 | 4.425 |
| 09:56 ET | 360 | 4.4333 |
| 10:01 ET | 600 | 4.425 |
| 10:03 ET | 611 | 4.42 |
| 10:08 ET | 100 | 4.39 |
| 10:10 ET | 110 | 4.3772 |
| 10:14 ET | 2975 | 4.38 |
| 10:17 ET | 4773 | 4.375 |
| 10:19 ET | 5632 | 4.4 |
| 10:21 ET | 18881 | 4.39 |
| 10:24 ET | 600 | 4.381 |
| 10:26 ET | 13082 | 4.415 |
| 10:28 ET | 2547 | 4.41 |
| 10:30 ET | 1000 | 4.4171 |
| 10:33 ET | 400 | 4.41 |
| 10:37 ET | 300 | 4.4151 |
| 10:39 ET | 358 | 4.4182 |
| 10:42 ET | 698 | 4.4049 |
| 10:44 ET | 100 | 4.405 |
| 10:46 ET | 100 | 4.41 |
| 10:50 ET | 25012 | 4.365 |
| 10:51 ET | 3621 | 4.39 |
| 10:53 ET | 348 | 4.39 |
| 10:55 ET | 1300 | 4.395 |
| 10:57 ET | 300 | 4.395 |
| 11:00 ET | 2700 | 4.395 |
| 11:02 ET | 1850 | 4.415 |
| 11:04 ET | 1003 | 4.42 |
| 11:06 ET | 322 | 4.42 |
| 11:09 ET | 7367 | 4.43 |
| 11:11 ET | 400 | 4.435 |
| 11:13 ET | 300 | 4.435 |
| 11:15 ET | 506 | 4.435 |
| 11:18 ET | 100 | 4.44 |
| 11:20 ET | 600 | 4.445 |
| 11:22 ET | 3601 | 4.45 |
| 11:27 ET | 300 | 4.44 |
| 11:29 ET | 600 | 4.45 |
| 11:33 ET | 300 | 4.454 |
| 11:36 ET | 935 | 4.46 |
| 11:38 ET | 250 | 4.4535 |
| 11:40 ET | 500 | 4.455 |
| 11:42 ET | 100 | 4.45 |
| 11:44 ET | 6481 | 4.42 |
| 11:45 ET | 1000 | 4.4226 |
| 11:49 ET | 736 | 4.43 |
| 11:51 ET | 600 | 4.44 |
| 11:56 ET | 100 | 4.445 |
| 11:58 ET | 100 | 4.445 |
| 12:00 ET | 100 | 4.445 |
| 12:02 ET | 500 | 4.44 |
| 12:05 ET | 858 | 4.44 |
| 12:07 ET | 200 | 4.445 |
| 12:09 ET | 594 | 4.445 |
| 12:14 ET | 300 | 4.425 |
| 12:16 ET | 300 | 4.43 |
| 12:20 ET | 200 | 4.435 |
| 12:21 ET | 852 | 4.42 |
| 12:23 ET | 100 | 4.425 |
| 12:38 ET | 200 | 4.42 |
| 12:39 ET | 810 | 4.425 |
| 12:41 ET | 3600 | 4.42 |
| 12:43 ET | 200 | 4.41 |
| 12:45 ET | 100 | 4.41 |
| 12:50 ET | 1270 | 4.4 |
| 12:52 ET | 2340 | 4.41 |
| 12:54 ET | 200 | 4.415 |
| 12:56 ET | 22287 | 4.38 |
| 12:57 ET | 1000 | 4.38 |
| 12:59 ET | 11605 | 4.375 |
| 01:01 ET | 5520 | 4.405 |
| 01:03 ET | 819 | 4.4016 |
| 01:06 ET | 9918 | 4.38 |
| 01:08 ET | 100 | 4.383 |
| 01:10 ET | 1006 | 4.375 |
| 01:12 ET | 300 | 4.375 |
| 01:14 ET | 3660 | 4.38 |
| 01:15 ET | 1400 | 4.39 |
| 01:19 ET | 400 | 4.38 |
| 01:21 ET | 1000 | 4.38 |
| 01:26 ET | 4107 | 4.3793 |
| 01:28 ET | 2406 | 4.38 |
| 01:30 ET | 420 | 4.38 |
| 01:32 ET | 300 | 4.375 |
| 01:33 ET | 2478 | 4.38 |
| 01:35 ET | 315 | 4.38 |
| 01:37 ET | 2000 | 4.365 |
| 01:39 ET | 4351 | 4.38 |
| 01:42 ET | 200 | 4.38 |
| 01:44 ET | 400 | 4.38 |
| 01:46 ET | 200 | 4.38 |
| 01:48 ET | 100 | 4.385 |
| 01:50 ET | 600 | 4.375 |
| 01:51 ET | 518 | 4.37 |
| 01:53 ET | 1400 | 4.38 |
| 01:55 ET | 4536 | 4.385 |
| 01:57 ET | 500 | 4.39 |
| 02:00 ET | 100 | 4.39 |
| 02:02 ET | 700 | 4.39 |
| 02:04 ET | 600 | 4.38 |
| 02:06 ET | 200 | 4.38 |
| 02:08 ET | 3300 | 4.39 |
| 02:09 ET | 200 | 4.385 |
| 02:11 ET | 300 | 4.38 |
| 02:13 ET | 200 | 4.395 |
| 02:15 ET | 200 | 4.39 |
| 02:20 ET | 400 | 4.395 |
| 02:22 ET | 800 | 4.405 |
| 02:26 ET | 600 | 4.415 |
| 02:27 ET | 300 | 4.41 |
| 02:29 ET | 3076 | 4.405 |
| 02:31 ET | 9275 | 4.46 |
| 02:36 ET | 487 | 4.445 |
| 02:38 ET | 300 | 4.442 |
| 02:40 ET | 400 | 4.445 |
| 02:42 ET | 2809 | 4.445 |
| 02:44 ET | 1100 | 4.4401 |
| 02:45 ET | 1193 | 4.44 |
| 02:47 ET | 910 | 4.445 |
| 02:49 ET | 802 | 4.44 |
| 02:51 ET | 1165 | 4.44 |
| 02:54 ET | 500 | 4.425 |
| 02:56 ET | 300 | 4.43 |
| 02:58 ET | 1889 | 4.425 |
| 03:00 ET | 400 | 4.43 |
| 03:02 ET | 312 | 4.42 |
| 03:03 ET | 100 | 4.412 |
| 03:05 ET | 200 | 4.41 |
| 03:09 ET | 448 | 4.405 |
| 03:12 ET | 400 | 4.4 |
| 03:14 ET | 300 | 4.39 |
| 03:16 ET | 2330 | 4.4 |
| 03:18 ET | 100 | 4.405 |
| 03:20 ET | 385 | 4.4 |
| 03:23 ET | 254 | 4.4 |
| 03:27 ET | 138 | 4.4 |
| 03:32 ET | 6599 | 4.4 |
| 03:34 ET | 420 | 4.395 |
| 03:36 ET | 1537 | 4.404 |
| 03:38 ET | 700 | 4.405 |
| 03:39 ET | 2095 | 4.4 |
| 03:41 ET | 640 | 4.4 |
| 03:43 ET | 1723 | 4.4 |
| 03:45 ET | 1150 | 4.4 |
| 03:48 ET | 1130 | 4.4 |
| 03:50 ET | 1368 | 4.395 |
Jun 3, 2024
DJ UniQure's AMT-130 Gets FDA RMAT Designation in Huntington's Disease, from 7:39AM ET on Monday Jun 03, 2024 by Dow Jones
7:39AM ET on Monday Jun 03, 2024 by Dow JonesuniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease, from 7:05AM ET on Monday Jun 03, 2024 by Dow Jones
7:05AM ET on Monday Jun 03, 2024 by Dow JonesuniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease, from 7:05AM ET on Monday Jun 03, 2024 by Dow Jones
7:05AM ET on Monday Jun 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Uniqure NV | 216.5M | -0.7x | --- |
MeiraGTx Holdings PLC | 270.7M | -3.3x | --- |
TriSalus Life Sciences Inc | 151.3M | -2.7x | --- |
Fennec Pharmaceuticals Inc | 169.4M | 165.2x | --- |
Lineage Cell Therapeutics Inc | 172.6M | -6.7x | --- |
Generation Bio Co | 188.3M | -1.1x | --- |
Company Information
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Contact Information
- Headquarters
- Paasheuvelweg 25aAMSTERDAM, Netherlands 1105 BP
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- David Meek
- Chief Executive Officer, Executive Director
- Matthew Kapusta
- Chief Financial Officer
- Christian Klemt
- Chief Operations Officer
- Pierre Caloz
- Chief Business and Scientific Officer
- Richard Porter
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $216.5M |
|---|---|
Revenue (TTM) | $19.0M |
Shares Outstanding | 48.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.96 |
EPS | $-6.20 |
Book Value | $4.34 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 11.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,383.61% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
